J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

Apple® today announced plans to expand in the Kingdom of Saudi Arabia, starting with the launch of the Apple Store® online in summer 2025. The online store will bring customers across Saudi Arabia new ...

The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & ...

Essentially serving as a one-stop shop for efficient equipment management, the Advantest KGD test cell solution helps reduce ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...